Category Archives: Covid-19

Le SARS-CoV-2 détériore les cellules ciliées et inhibe le mécanisme de clairance mucociliée dans les voies respiratoires

cellule ciliée infectée SARSCOV2

Des chercheurs ont montré que le SARS-CoV-2 se multiplie efficacement dans les voies respiratoires, qu’il cible principalement les cellules ciliées de l’épithélium et détruit leurs cils. Cette détérioration est associée à une inhibition du mécanisme de clairance mucociliée. Ce mécanisme permet d’évacuer les particules inhalées et protège les voies respiratoires des agents pathogènes. La perte des cils pourrait donc faciliter la propagation du virus plus profondément dans les voies respiratoires, jusqu’à ce qu’il atteigne les alvéoles pulmonaires et y déclenche une pneumopathie.

Confirmation of promising results from the CORIMUNO-TOCI-1 trial showing improved survival in patients with moderate to severe COVID-19 pneumonia

SARS-CoV-2

An article published in JAMA Internal Medicine and WHO meta-analysis of 27 controlled trials confirm the promising initial results of the test-CORIMUNO TOCI-1, indicating an improved prognosis of patients with moderate to severe COVID-19 pneumonia.

Interchangeability of COVID 19 mRNA vaccines: start of inclusions for the AP-HP – ARNCombi trial

The aim of the AP-HP – ARNCombi trial is to compare the immunological efficacy of the standard vaccine regimen with two doses of the same mRNA vaccine against Covid-19 with a regimen combining two different mRNA vaccines (one dose of Moderna vaccine after one dose of Pfizer vaccine or a dose of Pfizer vaccine after a dose of Moderna vaccine).

Regional organization in Ile-de-France and ECMO results in the management of extremely serious respiratory damage caused by Covid-19

hôpital

The teams of the cardiac and thoracic surgery departments and intensive medicine-intensive care of the Pitié-Salpêtrière hospital AP-HP, Sorbonne University and the Inserm, reported the results of the ECMO in the care of patients with extremely serious respiratory damage caused by Covid-19, and the regional organization set up by the Ile-de- France to deal with the pandemic.

Long COVID: 60% of Hospitalized Patients Still Have at Least One Symptom Six Months Later

Coronavirus SARS-CoV-2

In a new study, researchers show that a significant proportion of patients who were hospitalized and followed up as part of French COVID continue to have symptoms three and six months after infection.

COVID-19: discovery of the mechanisms of short- and long-term anosmia

Epithélium olfactif_SARS-CoV-2

Loss of smell, or anosmia, is one of the earliest and most commonly reported symptoms of COVID-19.

Point d’étape sur le projet de concert test à Marseille

concert test covid

Sommes-nous plus exposés au SARS-CoV-2 lors d’un concert doté d’un protocole sanitaire strict que dans notre vie quotidienne ? Voilà la question à laquelle les scientifiques de l’Inserm souhaitent répondre à travers une étude de santé publique promue par l’ANRS | Maladies infectieuses émergentes, en collaboration avec le collectif des professionnels du spectacle DO3ME et avec le soutien de la ville de Marseille et d’Aix Marseille université. Le protocole scientifique a rigoureusement été établi et la plupart des autorisations pour mener à bien cette étude ont été délivrées.

ComPaRe Covid long: development of the first scientific measure of the severity of the disease and its impact on the lives of patients

Researchers from the ComPaRe cohort (Community of Patients for Research, compare.aphp.fr ), led by Prof. Philippe Ravaud, AP-HP / University of Paris / Inserm, used an original method to develop and validate the first measurement science of the severity of the disease and its impact on the lives of patients.

Inserm and AstraZeneca join forces to test the efficacy of monoclonal antibody combination AZD7442 on Covid-19 in the European DisCoVeRy trial

SARS-CoV-2

A long-acting antibody (LAAB) combination developed by AstraZeneca is to be evaluated in DisCoVeRy, the Inserm-coordinated European trial aimed at finding a treatment for COVID-19.

COVIDOM – Study on the clinical characteristics and factors associated with hospitalization or death of ambulatory patients monitored remotely

SARS-CoV-2

Teams from AP-HP, Sorbonne University and Inserm at the Pierre Louis Institute of Epidemiology and Public Health, coordinated by Dr Youri Yordanov and Prof. Agnès Dechartres, assessed the clinical characteristics, fate and factors associated with hospitalization or death of ambulatory patients followed using the COVIDOM device.

fermer
fermer
RSS Youtube